Meeting
2017 ASCO Annual Meeting
Phase 1 results of PTC596, a novel small molecule targeting cancer stem cells (CSCs) by reducing levels of BMI1 protein.
Authors
Jeffrey R. Infante
Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN
Jeffrey R. Infante , Philippe L. Bedard , Geoffrey Shapiro , Todd Michael Bauer , Amy Prawira , Oscar Laskin , Marla Weetall , John Baird , Art Branstrom , Edward O'Mara , Robert J. Spiegel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02404480
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2574)
DOI
10.1200/JCO.2017.35.15_suppl.2574
Abstract #
2574
Poster Bd #
66
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A.
First Author: Antonio Jimeno
Poster
2013 ASCO Annual Meeting
Pharmacokinetics and safety of an oral ALK inhibitor, ASP3026, observed in a phase I dose escalation trial.
First Author: Amita Patnaik
Poster
2023 ASCO Annual Meeting
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors.
First Author: Chia-Chi Lin
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk